AP1189   Click here for help

GtoPdb Ligand ID: 11292

Synonyms: AP-1189 | example 19 [WO2007141343A1]
Compound class: Synthetic organic
Comment: AP1189 is a biased agonist of melanocortin (MC) receptors. It was designed to elicit the proresolving properties of the MC1 and MC3 receptors in inflammation, whilst sparing their melanogenic effects [2]. This is achieved by bias towards ERK1/2 phosphorylation and and Ca2+ mobilisation rather than inducing canonical cAMP production. The chemical structure is claimed in Action Pharma's patent WO2007141343A1 (compound 2/example 19) [1].

SARS-CoV-2 and COVID-19: The proresolving activity of AP1189 is being investigated as a mechanism to combat the dysfunctional immune response in COVID-19 patients.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 124.31
Molecular weight 298.12
XLogP 2.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES NC(=N/N=C\C=C\c1cccn1c1ccccc1[N+](=O)[O-])N
Isomeric SMILES NC(=N/N=C\C=C\c1cccn1c1ccccc1[N+](=O)[O-])N
InChI InChI=1S/C14H14N6O2/c15-14(16)18-17-9-3-5-11-6-4-10-19(11)12-7-1-2-8-13(12)20(21)22/h1-10H,(H4,15,16,18)/b5-3+,17-9-
InChI Key ZSDGHWLLLGYAJV-LDRJOUGUSA-N
No information available.
Summary of Clinical Use Click here for help
AP1189 has been advanced to clinical investiagtions in rheumatoid arthritis and idiopathic membranous nephropathy. SynAct Pharma (as part of the RESOVIR (Resolution in Viral infection) scientific collaboration between Universidade Federal de Minas, Brazil and Barts and the London School of Medicine, UK) have initiated a Phase 2 clinical study to evaluate the safety and efficacy of AP1189 in COVID-19 confirmed patients with early signs of acute respiratory distress syndrome (ARDS). The primary clinical objective is to demonstrate a reduction in time to respiratory recovery (normalisation of oxygen saturation on ambient air).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04456816 A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN Phase 2 Interventional SynAct Pharma Aps
NCT04004429 A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease Phase 2 Interventional SynAct Pharma Aps